Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Modest growth for Bayer diagnostics:

This article was originally published in Clinica

Executive Summary

The diagnostics and diabetes care segment of Bayer HealthCare grew by 3.8% in the first quarter, to E461m ($586m). The company said negative currency effects reduced the growth by two percentage points. Diagnostics grew at 5% to E318m, driven by lab testing systems and near-patient testing. Diabetes care product sales of E143m were up by 1.4%, an increase the company attributed to a strong performance in Europe. Earnings before interest and tax rose by E9m to E37m. Bayer group sales were up 15.7% to E6.7bn, with EBIT before special items up 50.1% to E1.1bn.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel